Application of 18F-FDG PET in the diagnosis and evaluation of SARS-CoV-2 infection and related events
10.3760/cma.j.cn321828-20221025-00320
- VernacularTitle:18F－FDG PET在新型冠状病毒感染及相关事件诊断和评估中的应用
- Author:
Rou LI
1
;
Lan ZHANG
;
Danni LI
;
Changjing ZUO
;
Xiao LI
Author Information
1. 海军军医大学第一附属医院核医学科，上海 200433；
- Keywords:
Coronavirus infections;
Positron-emission tomography;
Fluorodeoxyglucose F18;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(7):429-432
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly ravaged the world and infected hundreds of millions of people since its outbreak. Early diagnosis of COVID-19 is conducive to the control of virus transmission and the timely treatment of patients. Among the imaging techniques, chest CT is an important basis for the diagnosis and evaluation of COVID-19. 18F-FDG PET is not generally recommended as a routine diagnostic tool for COVID-19, but it plays an important role in the assessment of SARS-CoV-2-related events based on the characteristic of whole-body multi-systemic scan and functional imaging diagnosis. In this paper, the application of 18F-FDG PET in COVID-19 diagnosis, prognostic evaluation and long-term sequelae evaluation, and clinical performance of 18F-FDG PET after COVID-19 vaccine are summarized on the basis of literature research and clinical reports analysis. Furthermore, the application and development direction of other new molecular probes for nuclear medicine in COVID-19 are prospected.
